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Abstract  
 
Objectives: We investigated safety and efficacy of combining transcatheter valve 
replacement (TAVR) and left atrial appendage occlusion (LAAO) versus TAVR 
alone.  
Background: Patients with severe aortic stenosis and atrial fibrillation undergoing 
TAVR are at increased risk for stroke and bleeding complications.  
Methods:  A cohort of 52 patients undergoing concomitant TAVR and LAAO were 
compared to 52 patients undergoing isolated TAVR. A primary safety endpoint at 30 
days, a clinical efficacy endpoint from day 30 to last follow-up and a LAAO efficacy 
endpoint from the first postinterventional day to the last follow-up were chosen.  
Results: Mean age of the study population was 85 ± 5 years. Mean CHA2DS2-Vasc-
score and HASBLED score were 3.9  1.1 and 2.6  0.9, respectively. Mean STS 
score was 7.8  5.5. Median follow-up of the study population was 9.4 (range 0-48) 
months. The primary safety endpoint occurred in 10 patients in the concomitant and 
in 7 patients in the isolated TAVR group (19% vs. 14%, 95% confidence interval, 
CI 0.59 to 4.06). The clinical and LAAO efficacy endpoints were achieved in 81 
(79%; 75% vs. 82%, 95% confidence interval, CI 0.49 to 2.92) and 75 patients 
(73%; 69% vs. 76%, 95% confidence interval, CI 0.54 to 2.51), respectively.  
Conclusion: This pilot study shows that concomitant TAVR and LAAO is feasible 
and seems to be safe among patients with severe aortic stenosis and atrial fibrillation. 
Larger trials and longer follow-up is needed to confirm safety and efficacy of such an 
approach.  
 
Key words: atrial appendage, atrial fibrillation, stroke prevention, TAVR, LAAO 
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Condensed abstract 
Patients with severe aortic stenosis and atrial fibrillation undergoing transcatheter 
valve replacement (TAVR) are at increased risk for stroke and bleeding 
complications.  
We investigated clinical outcome (safety and efficacy) of concomitant TAVR and left 
atrial appendage occlusion (LAAO) in 104 patients (52 undergoing TAVR/LAAO, 52 
undergoing isolated TAVR).  
This pilot study shows that concomitant TAVR and LAAO is feasible and seems to be 
safe. However larger trials and longer follow-up is needed to confirm these results.  
 
 
 
 
 
 
Abbreviation list 
  
ACP = AMPLATZER Cardiac Plug  
AF = atrial fibrillation 
LAA = left atrial appendage 
LAAO = left atrial appendage occlusion 
OAC = oral anticoagulation 
TAVR = transcatheter aortic valve replacement 
TEE = transesophageal echocardiography 
TIA = transient ischemic attack 
TTE = transthoracic echocardiography 
VARC = Valve Academic Research Consortium 
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Introduction 
Over the past decade, transcatheter aortic valve replacement (TAVR) has emerged as 
preferred treatment modality for patients with severe aortic stenosis at high surgical 
risk and is now expanding to lower risk patients(1-3). Atrial fibrillation (AF) occurs 
in more than 10% in octogenarians and is the most common arrhythmia in the TAVR 
population. It is associated with substantial morbidity and mortality, particularly due 
to early and late embolic stroke(4-7), bleeding complications(8) and impaired overall 
outcome(7,8). 
To prevent thromboembolic strokes in patients with AF, oral anticoagulation (OAC) 
is the standard treatment, for patients with a CHA2DS2-VASc score of ≥1(9). 
However, OAC carries a substantial risk of major bleeding complications(10). The 
combination of OAC with antiplatelet agents after TAVR potentiates the risk for 
major bleeding complications(11). In AF patients undergoing TAVR, bleeding 
complications were reported to be as high as 50% and in those who suffer a bleeding 
complication during the first year, 1-year mortality is doubled(8). Therefore, the 
increased risk for serious bleeding precludes the use of OAC in a significant 
proportion (30% to 50%) of eligible patients due to relative or absolute 
contraindications or due to physician or patient preference(12). 
 
Balancing the risk of embolic and bleeding events in this high-risk population 
represents a major clinical challenge. Left atrial appendage occlusion (LAAO) offers 
a non-pharmacologic stroke protection, obviating the need for OAC. It may therefore 
be an attractive treatment for the AF TAVR population(13,14)  (Figure 1).  
We investigated safety and short-term efficacy of combined procedures (TAVR and 
LAAO) versus TAVR alone in a contemporary TAVR population suffering from AF. 
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Methods 
Patients 
This is an observational study on consecutive patients undergoing TAVR at the 
university hospitals of Zurich (463 patients) and Bern (707 patients) from February 
2011 to June 2015. Decision on whether to perform concomitant LAAO or not was 
random, based on patients’ wish, operator and treating Cardiologists’ preference. All 
patients suffered from severe aortic stenosis (mean transaortic systolic pressure 
gradient of ≥40mmHg, or an aortic valve area of <1.0cm2 or <0.6cm2/m2) and were 
deemed appropriate candidates for TAVR as assessed by the local Heart Team. All 
patients had AF with a CHA2DS2-Vasc score of ≥1. Patients were dichotomized into a 
“concomitant group” (TAVR and LAAO during the same procedure) and an “isolated 
TAVR group” (TAVR alone and medical therapy for stroke prevention). All patients 
gave written informed consent for the procedure and data collection. Patients were 
followed within the nationwide Swiss TAVR registry, which was approved by the 
local ethics committees.  
 
Device 
The AMPLATZER Cardiac Plug (ACP) (St. Jude Medical, Plymouth, MN, USA) is 
made of nitinol mesh and filled by polyester to enhance endothelialization and to 
prevent blood flow through the device. The ACP consists of a lobe with tiny 
anchoring hooks and a sealing disc. Lobe and disk are connected by a thin, stretchable 
waist. The ACP is available in lobe sizes from 16 to 30mm, requiring a 9 to 13 French 
TorqVue delivery sheath (St. Jude Medical, Plymouth, MN, USA). The second 
generation device ACP (Amulet) has a recessed screw on the disc to prevent clot 
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formation. Additionally, the lobe comes in larger size ranges (16 - 34mm) and 
requires a 12 or 14 French sheath. The larger sizes also feature more anchoring hooks. 
 
Procedure  
TAVR was performed using either a transfemoral procedure or in, case of limiting 
peripheral arterial disease, a transapical, subclavian, or direct aortic access. Balloon-
expandable as well as self-expandable valve systems were used. Prosthesis size was 
selected on the basis of annulus measurements by multislice computed tomography or 
transesophageal echocardiography (TEE).  
In patients with concomitant interventions, LAAO was performed during the same 
sitting, usually after TAVR. Preprocedural imaging of the left atrial appendage (LAA) 
comprised a TEE in all patients. Procedural guidance, for both TAVR and LAAO was 
strictly based on fluoroscopy, to avoid general anesthesia (except in cases of a 
transapical or transaortic access). Safety of fluoroscopy-guided LAAO has been 
previously described by our group(15). The left atrium was accessed by transseptal 
puncture or through a patent foramen ovale (PFO) or atrial septal defect (ASD)(16). 
Using a Backup Meier wire (Boston Scientific, Natick, MA, USA) the transseptal 
sheath was exchanged for the 13 French Amplatzer 45°-45°-TorqVue sheath (St. Jude 
Medical, Plymouth, MN, USA) for delivery of the ACP. Device sizing relied on 
contrast injections to the LAA in different angulations. Given the known outer 
diameter of the delivery sheath (e.g., 5.5mm) an adequately sized ACP was chosen, 
aiming for at least 20% oversizing. After device deployment, a stable device position 
was confirmed by a tug test and contrast injections. Finally the device was released. 
A transthoracic echocardiogram (TTE) was performed before hospital discharge to 
confirm a stable position of the ACP.  
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In the concomitant TAVI and LAAO group, oral anticoagulation was discontinued 
immediately after LAAO, and patients received dual antiplatelet therapy with long-
term acetylsalicylic acid (100mg) and clopidogrel (75mg) for 1–6 months. Patients 
undergoing isolated TAVR were continued on oral anticoagulation in combination 
with dual or single antiplatelet therapy.  
 
Follow-up 
Patients with combined interventions underwent a TEE after 3-6 months to confirm a 
proper sealing of the LAA and to identify residual leaks or thrombi on the device. All 
patients had TTE performed at 1 and 12 months after the intervention to confirm 
proper functioning of the aortic valve prosthesis. Clinical follow-up was performed at 
the time of TEE and TTE visits. In case of an event, hospital charts were reviewed, or 
the cardiologist or primary care physician was contacted. An independent clinical 
event committee adjudicated all adverse events according to current criteria. 
 
Endpoints  
Three primary endpoints were adapted from Valve Academic Research 
Consortium (VARC)-2 standardized endpoint definitions(17) by including LAAO-
specific events.  
The primary safety endpoint at 30-days was a composite of all-cause mortality, stroke 
(disabling and non-disabling) and TIA, bleeding (life-threatening), acute kidney 
injury stage 2-3 (according to the AKIN system), major vascular complications, 
clinically significant pericardial effusion requiring pericardiocentesis or resulting in 
cardiac tamponade, device embolization, and valve failure.  
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The efficacy endpoints were divided into a ‘clinical efficacy endpoint’ and a ‘LAAO 
efficacy endpoint’. The clinical efficacy endpoint included events from day 30 to last 
follow-up and was defined as freedom from all-cause mortality, all-cause stroke 
(disabling and non-disabling), and bleeding (life threatening and major) events. The 
LAAO efficacy endpoint was defined as freedom from all-cause mortality, all-cause 
stroke (disabling and non-disabling) and TIA, and bleeding (life-threatening and 
major) occurring from the first postinterventional day to the last follow-up.  
 
Statistical analysis 
Data are presented as mean (SD) or frequency as appropriate. Baseline patient 
characteristics between groups (e.g., concomitant TAVR/LAAO vs. isolated TAVR) 
were compared by unpaired parametric and non-parametric tests as appropriate. For 
the composite endpoints, time-to-event after intervention was estimated by the 
Kaplan-Meier method. 95%-confidence intervals estimated by bivariate cox 
regression are presented for the composite and single endpoints between groups. 
Multivariable Cox regression analysis controlling for age at intervention, sex, and 
CHA2DS2-Vasc, HAS-BLED, and STS scores was used to further assess the effect of 
concomitant LAAO on the composite endpoints. A two-sided p-value ≤0.05 was 
considered statistically significant for the comparison of the baseline patient 
characteristics between groups. We did not attempt inferential hypothesis testing  for 
the composite and single endpoint comparisons, thus 95%-confidence intervals rather 
than p-values are presented. Statistical analyses were performed using STATA 
version 13.1 (Stata Corp, TX, USA). 
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Results 
Patient Characteristics 
The study population comprised 104 patients (59 males; mean age 85  5 years). 
Mean CHA2DS2-Vasc score was 3.9  1.1, mean HASBLED score was 2.6  0.9, and 
mean STS score was 7.8  5.5. A history of arterial hypertension was present in 81 
(78%), diabetes mellitus in 33 (32%), prior ischemic stroke or TIA in 14 (14%), and 
coronary heart disease in 53 patients (51%). Five patients (5%) were on dialysis. No 
significant differences in baseline characteristics were present between the two groups 
(Table 1). 
 
Procedural information 
Procedures were performed at the University Hospital Zurich (80 patients, 77%) and 
at Bern University Hospital  (24 patients, 23%) between October 2009 and March 
2015. Of the 104 patients, 52 underwent TAVR and LAAO in the same procedure 
(concomitant group), whereas 52 patients underwent TAVR alone (isolated TAVR 
group). For TAVR, a transfemoral approach was chosen in 92% (85% in the 
concomitant group, 90% in the isolated TAVR group), a transapical access in 6% 
(12% in the concomitant group, 8% in the isolated TAVR group), a direct aortic 
access in 1% (0% in the concomitant group, 2% in the isolated TAVR group), and a 
left subclavian access in 1% (2% in the concomitant group, 0% in the isolated TAVR 
group).  The CoreValve prosthesis (Medtronic, Minneapolis, MN) was implanted in 
21 (40%) patients, an Edwards SAPIEN XT in 19 (36%) patients, an Edwards 
SAPIEN 3 (Edwards Lifesciences,Ivine, CA) in 7 (14%) patients, a Lotus valve 
(Boston Scientific, Marlborough, MA) in 2 (4%) patients, and an Acurate TA valve 
(Symetis SA, Ecublens, Switzerland), a St. Jude Portico valve (St. Jude Medical, Inc, 
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St Paul, MN), and a Direct Flow Medical valve (Direct Flow Medical Inc., Santa 
Rosa, CA) each in 1 (2%) patient. No differences in valve distribution between the 
‘concomitant group’ and the ‘single TAVR group’ (p=0.439) was observed. Besides 
TAVR and LAAO, 18 patients (17%) had additional interventions: 15 patients (29%) 
in the concomitant group (percutaneous coronary intervention in 8 patients (15%), 
iliofemoral stenting in 3 patients (6%), PFO or ASD closure in 3 patients (6%), and 
MitraClip in 1 patient (2%)) and three patients (6%) in the isolated TAVR group 
(percutaneous coronary intervention in 2 patients (4%) and PFO closure in 1 patient 
(2%)). 
 
Procedural and safety outcome at 30 days 
The primary safety endpoint occurred in 10 patients in the concomitant group and in 7 
patients in the isolated TAVR group (19% vs. 14%, 95% confidence interval, CI 
0.59 to 4.06, Table 2, Figure 2). Multivariate analysis did not reveal any evidence for 
a difference between groups (95% confidence interval, CI 0.59 to 4.29).  
There was no procedural neurologic complication. Three patients died during the first 
30 days after the intervention, 1 in the concomitant and 2 in the isolated TAVR group. 
Of those, 2 were cardiovascular (1 in each group) and 1 was a non-cardiovascular 
death. The non-cardiovascular death occurred 3 weeks after TAVR and was due to 
urosepsis complicated by multi-organ failure. One cardiovascular death (isolated 
TAVR group) occurred directly after successful TAVR due to global ischemia with 
sustained ventricular fibrillation resistent to defibrillation. The other cardiovascular 
death (concomitant group) happened two weeks after the procedure and was due to 
worsening heart failure. None of the deaths was associated with LAA occlusion. 
During the first month of follow-up, 1 disabling stroke of ischemic origin (persistent 
11 
 
hemiparesis, dysarthria, and dysphagia presumably due to a thromboembolic event 
arising from a thrombus on the LAAO) occurred in the concomitant group and 3 
neurologic events in the isolated TAVR group (1 TIA and 2 minor ischemic strokes). 
In the patient with the disabling ischemic stroke, OAC was restarted and continued. 
In both groups there was 1 life-threatening bleeding complication: 1 bleeding was due 
to femoral arteriovenous fistula (concomitant group), and in 1 patient gastrointestinal 
bleeding occurred 4 days after the initial intervention due to multiple duodenal ulcers 
(isolated TAVR group). As expected, use of contrast dye was higher in the 
concomitant group when compared to the isolated TAVR group (312 ±	148ml	in	the	
concomitant	group	vs.	98	±	74ml	in	the	isolated	TAVR	group). Five patients 
suffered from acute kidney injury (2 patients with AKIN stage 1 and 3 patients with 
AKIN stage 3), 4 in the concomitant and 1 in the isolated TAVR group. Three 
procedural access site complications occurred in the concomitant group (1 femoral 
perforation and 1 arteriovenous fistula with a relevant hematoma, both treated with a 
Fluency covered stent; and 1 dissection of the femoral artery, that was treated with 
uncovered stents).  
Cardiac tamponade occurred in 1 patient directly after LAAO and was successfully 
treated with pericardiocentesis without any long-term sequelae. In 1 patient 
transthoracic echocardiography 1 day after the intervention revealed an embolized 
LAA occluder in the left ventricle. The device was percutaneously snared and 
removed. The patient then underwent successful implantation of another device. 
 
Follow-up and efficacy outcome 
Median (range) follow-up of the study population was 9.4 (0-48) months. The 
composite clinical efficacy endpoint was achieved in 39 patients in the concomitant 
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group and in 42 patients in the isolated TAVR group (75% vs. 82%, 95% confidence 
interval, CI 0.49 to 2.92, Table 3, Figure 3). The LAAO efficacy endpoint was 
achieved in 36 patients in the concomitant, and in 39 patients in the isolated TAVR 
group (69% vs. 76%, 95% confidence interval, CI 0.54 to 2.51, Table 3, Figure 4). 
Multivariate analysis did not reveal a difference between concomitant and isolated 
interventions for the composite clinical efficacy (95% confidence interval, CI 0.55 
to 3.71) and the LAAO efficacy endpoint (95% confidence interval, CI 0.52 to 
2.63). 
At last follow-up, 83 patients (81%) of the total study population were alive. Deaths 
occurred in 21 patients (20%), of which 18 (86%) were late deaths (>30 days after the 
initial procedure). Ten patients died in the concomitant and 8 in the isolated TAVR 
group (19% vs. 15%). None of the deaths was directly associated with LAAO. Eight 
deaths were cardiovascular (5 patients in the concomitant and 3 patients in the 
isolated group) and 10 were non-cardiovascular (5 patients in each group). 
Cardiovascular deaths included 1 patient with coronary triple-vessel disease with 
sudden cardiac death (concomitant group), 1 patient with progressive heart failure (3 
patients in the concomitant and 2 in the isolated TAVR group), and 2 unknown deaths 
(1 patient in each group). Non-cardiovascular deaths occurred due to multi-organ 
failure caused by sepsis in 4 patients (2 patients in each group), progressive renal 
failure in 2 patients (both in the concomitant group), subdural hematoma due to 
recurrent falls 10 months after the initial procedure in 1 patient (concomitant group), 
tongue carcinoma in 1 patient (isolated TAVR group), progressive dementia in 1 
patient (isolated TAVR group), and 1 patient decided to discontinue dialysis due to 
his co-morbidities (isolated TAVR group).  
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Two patients (1 in each group) suffered from late life threatening bleeding and 3 
patients (concomitant group) had major bleeding complications (all due to 
gastrointestinal bleeding).  
At the time of bleeding 2 of these patients received acetylsalicylic acid therapy alone 
and 1 was under dual antiplatelet therapy (acetylsalicylic acid therapy and 
clopidogrel). Life threatening bleeding included the patient with subdural hematoma 
due to recurrent falls (concomitant group) and 1 patient with upper gastrointestinal 
bleeding under supratherapeutic oral anticoagulation with warfarin.  
 
OAC was continued for some additional period after LAAO in 5 (10%) of the 52 
patients. The reasons varied among patients: thrombus on the device (2 patients), 
physician order (1 patient), heparin induced thrombocytopenia (1 patient), and 
unknown reasons (1 patient). The 2 patients with a thrombus on the device continued 
with OAC due to physician order and patient wish. In the patient with heparin-
induced thrombocytopenia, OAC with rivaroxaban 20 mg was continued for 6 weeks 
after the intervention. Eight patients (16%) in the isolated TAVR group received no 
OAC. Duration and type of antiplatelet therapy varied among patients and depended 
on physician order. In the isolated TAVR group, 8 patients (16%) at discharge were 
treated with triple therapy (acetylsalicylic acid, clopidogrel, and OAC); 24 patients 
(47%) received dual therapy (either acetylsalicylic acid or clopidogrel and OAC), 11 
patients (22%) received oral anticoagulation alone; 7 patients (14%) were treated with 
acetylsalicylic acid and clopidogrel or ticagrelor, 1 patient was on clopidogrel alone. 
Of those patients receiving OAC most were treated with warfarin (86%) and 
additional antiplatelet therapy was prescribed for 1 to 12 months.  
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Discussion 
The goal of this pilot study in patients with severe aortic stenosis was to investigate 
outcomes of combined procedures (TAVR and LAAO) and TAVR alone. The main 
findings were that (1) combining TAVR with LAAO was safe and did not result in 
adverse procedural outcome; (2) there was no difference in efficacy after a mean 
follow-up of 9.4 months; and (3) these findings held true after multivariate analysis 
adjusted for age, sex, and CHA2DS2-Vasc, HASBLED, and STS scores; and (4) most 
(88%) safety events occurred in the first 7 days after the intervention. 
 
Procedural and clinical safety outcome 
As previously shown, LAAO has the potential to prevent ischemic stroke as well as 
bleeding complications in patients with AF(13,14,18). Since patients in AF 
undergoing TAVR are at high risk for bleeding and thromboembolic events, 
combining TAVR and LAAO appears as a reasonable approach to prevent these 
complications. However, LAAO is a technically demanding procedure with a flat 
learning curve(15,16). Therefore, complication rates of LAAO are clinically 
significant and strongly related to operator experience(19,20). Due to the additional 
venous access, the transseptal puncture, the increased procedural time, and the extra 
contrast-dye required, LAAO after TAVR potentially bears an increased risk of 
adverse procedural events. However, our results suggest, that the procedure can be 
performed safely in addition to TAVR in experienced hands.  
In line with recently published data, most safety events (88%) in the present study 
were a result of periprocedural complications or occurred early after the intervention 
(<7 days)(13,21). Safety events strictly related to LAAO, such as cardiac tamponade 
and embolization of the LAA closure device, occurred in only 2 patients (5%). Device 
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embolization was previously reported in 0.8 - 3.9% and is mainly limited to the early 
post procedural period(18,22). Cardiac tamponade in our patient cohort was low (2%) 
in line with published data (1.2 - 5%)(13,18,19) and neither device embolization(23) 
nor tamponade did result in any long-term sequelae.  
Although periprocedural complications are thought to be higher in patients 
undergoing concomitant TAVR and LAAO, we did not observe higher 30-day event 
rates of clinical significant bleeding (2%), access site complications (6%), and acute 
kidney injury stage 2-3 (8%) when compared to studies with patients undergoing 
TAVR alone. 30-day outcome of recent trials with patients undergoing TAVR show 
event rates of major vascular complications of 5.3 - 6.5%, clinically significant 
bleeding of 4.0 - 13.6%, and acute kidney injury of 2.7 - 18.7%(3,24,25). A word of 
caution is needed for patients with reduced kidney function, since concomitant 
procedures required a higher procedural amount of contrast dye. On the other hand, 
patients with kidney failure are exposed to a higher bleeding risk and may particularly 
benefit from concomitant LAAO. Of note, in the concomitant patient population 
additional procedures (besides LAAO) were performed much more frequently than in 
the isolated TAVR group (29% vs. 6%).  
In summary, concomitant LAAO in patients undergoing TAVR does not seem to 
affect the success rate or outcome of TAVR.  
 
Clinical and LAAO efficacy outcome 
After 3.8 years of follow-up, superiority of LAAO as compared to OAC with warfarin 
was shown in a randomized trial(14), which was in line with a large multi-center 
registry with ACP(18) with a follow-up of 13 months. The potential advantage of 
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LAAO over vitamin K antagonists (i.e. reduction of bleeding and ischemic stroke) 
became more prominent with longer follow-up(15,26).  
In our study we could not show any difference in efficacy outcomes between the two 
groups, presumably due to a too short follow-up and small patient number (9.4 
months as compared to 3.8 years and 13 months, respectively in the previously 
mentioned studies including a larger number of patients). However, it is likely that the 
advantage of LAAO becomes only evident after longer follow-up. Furthermore, 
ischemic strokes were a relatively rare event in our study population, thereby further 
limiting statistical power. 
The second composite LAAO efficacy endpoint was chosen to assess early efficacy, 
excluding procedural events, which account for the largest share according to the 
PROTECT-AF trial. Although warfarin was stopped directly after LAAO in most 
patients, no difference in the composite of mortality, neurological events, and 
bleeding complications was noted. As mentioned above, this finding supports the 
evidence that the benefit of LAAO over vitamin K antagonists materializes, if at all, 
only after a longer follow-up period.  
Another interesting finding is the diversity of antithrombotic regimens in the isolated 
TAVR group. Given the high-risk population, treating physicians seem reluctant to 
put TAVR patients on oral anticoagulation. This in return puts those patients at very 
high risk for stroke complications(27), indicating the dilemma we are facing in these 
patients.  
LAAO seems to be a valuable alternative for oral anticoagulation especially in these 
high-risk patients. The question remains, however, if concomitant procedures are 
preferable to a staged approach, as described in a case report by Bogunovic et al.(28). 
In our opinion concomitant procedures are not only feasible in experienced hands but 
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also have several advantages: patients undergoing TAVR and LAAO in the same 
sitting are immediately protected from stroke and bleeding complications and a single 
session approach seems patient-friendly for elderly and multimorbid patients(29). 
 
Study limitations 
The main goal of this pilot study was an initial proof of concept to demonstrate the 
safety of combining TAVR with LAAO. Conclusions on safety and efficacy are only 
hypothesis generating, since the main limitation of the study arises from the relatively 
small number of patients and the short follow-up, which limits the power of the 
analysis. Certain design limitations are inherent, including the retrosprective nature of 
this study and the possible selection bias due to the lack of selecting a propensity 
matched cohort. However, comparison of the ‘isolated TAVR group’ to the remaining 
patients with atrial fibrillation in the TAVR cohort of the University hospital Zurich 
shows no remarkable difference in risk factors (STS score, sex, diabetes, 
hypertension, stroke and coronary artery disease).  
LAAO is considered an intricate procedure, coming along with a flat learning curve. 
Therefore, our results may represent the outcomes of high-volume centres with many 
years of experience with LAAO and may therefore not be generalizable. 
Further, the diversity of therapeutic regimens for OAC might have influenced 
outcomes of the presented study population. Therefore, a larger, randomized study is 
needed to show safety and efficacy of combined interventions. For a future study, the 
total estimated sample size for the composite safety endpoint based on 80% power to 
confirm non-inferiority (one-sided confidence level of 97.5%) would be 484 
(assuming an event rate of 19% and considering that a difference in the composite 
safety event rate as large as 10% in favour of the single TAVI procedure would allow 
18 
 
the concomitant TAVI procedure to be non-inferior).   
 
Conclusions 
Combining TAVR with LAAO is feasible and seems to be safe. A larger randomized 
trial with longer follow-up is needed to confirm safety and to further show efficacy of 
combining these two interventions. 
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Clinical Perspectives 
 
Patients with severe aortic stenosis and atrial fibrillation undergoing transcatheter 
aortic valve replacement (TAVR) are at increased risk for stroke and bleeding 
complications. Left atrial appendage occlusion (LAAO) offers a non-pharmacologic 
stroke protection, obviating the need for oral anticoagulation. Combining TAVR and 
LAAO in the same sitting is feasible and seems to be safe. However, to show safety 
and efficacy of combining TAVR and LAAO in these patients, a larger randomized 
trial with longer follow-up is needed. 
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Table 1.	Baseline characteristics. 
	 Overall	population	
(n	=104	)	
Concomitant	
(n	=52	)	
Isolated	TAVR	
(n	=52)	 	
p‐value	
Age,	yrs	 84.6	±	5.0	 84.6	±	5.7	 84.7	±	4.3	 0.969	
Male	 59	(57)	 29	(56)	 30	(58)	 0.843	
CHA2DS2‐Vasc	score	 3.9	±	1.1	 4.1	±	1.2	 3.8	±	0.9	 0.232	
HAS‐BLED	score	 2.6	±	0.9	 2.7	±	1.0	 2.5	±	0.9	 0.258	
STS	score	 7.8	±	5.5	 8.0	±	5.3	 7.5	±	5.7	 0.301	
Hypertension	 81	(78)		 40	(77)	 41	(79)	 0.813	
Diabetes	mellitus	 33	(32)	 18	(35)	 15	(29)	 0.527	
Paroxysmal	atrial	fibrillation	 45	(43)	 24	(46)	 21	(40)	 0.553	
NYHA	functional	Class	 	 	 	 0.225	
II	 28	(27)	 12	(23)	 16	(31)	 	
III	 56	(54)	 33	(64)	 23	(44)	 	
IV	 18	(17)	 6	(12)	 12	(23)	 	
Prior	ischemic	stroke	or	TIA	 14	(14)	 6	(12)	 8	(15)	 0.566	
CHD	 53	(51)	 26	(50)	 27	(52)	 0.844	
LVEF,	%	 53.2	±	12.4	 53.9	±	11.2	 52.6	±	13.5	 0.599	
Mean	aortic	valve	gradient,	mmHg	 44.3	±	17.1	 44.3	±	17.6	 44.3	±	16.8	 0.997	
Aortic	valve	Area,	cm2	 0.70	±	0.2	 0.69	±	0.2	 0.72	±	0.2	 0.473	
Dialysis	 5	(5)	 3	(6)	 2	(4)	 0.647	
	
Values are mean ± SD or n (%).  
CHD = coronary heart disease; CHA2DS2‐Vasc = congestive heart failure, 
hypertension, age >75 years, diabetes mellitus, and prior stroke of transient ischemic 
attack; CHD = coronary heart disease; HAS-BLED = uncontrolled hypertension > 
160 mmHg, renal disease (dialysis, transplant, creatinine > 200µmol/l), liver disease 
(cirrhosis or bilirubin >2x normal or AST/ALT/AP > 3x normal), prior stroke, prior 
major bleeding or predisposition to bleeding, labile INR (time in therapeutic range < 
60%), age > 65 years, medication usage predisposing to bleeding (antiplatelet agents, 
non-steroidal antirheumatic drugs), alcohol or drug usage (≥8 drinks/week); LVEF = 
left ventricular ejection fraction; NYHA = New York Heart Association; STS score = 
The Society of Thoracic Surgeons risk score; TIA = transient ischemic attack.  
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Table 2. Safety outcome of combined interventions vs. TAVR alone. 
	 Overall		(n	=104	)	
Concomitant	
(n	=52)	
Isolated	TAVR	
(n	=52)	
95%	conf.	
intervall 
*Composite	safety	endpoint		 17	(16)	 10	(19)	 7	(14)	 0.59	‐	4.06	
	 All‐cause	mortality	 3	(3)	 1	(2)	 2		(4)	 0.46	‐	5.59	
	 	 Cardiovascular	 2	(2)	 1	(2)	 1	(2)	 0.06	‐	15.99	
	 	 Non‐cardiovascular	 1	(1)	 0		 1	(2)	 0	
	 Stroke	and	TIA	 4	(4)	 1	(2)	 3	(6)	 0.33	‐	3.06	
	 	 Ischemic	stroke	 3	(3)	 1	(2)	 2	(4)	 0.044	‐	5.37	
	 	 Hemorrhagic	stroke	 0	 0	 0	 	
Life‐threatening	bleeding	 2	(2)	 1	(2)		 1	(2)	 0.06	‐	15.83	
	 Acute	kidney	injury	(stage	2‐3)	 5	(5)	 4	(8)	 1	(2)	 0.45	‐	36.24	
	 Major	vascular	complication	 3	(3)	 3	(6)	 0	 0	
						Pericardial	tamponade	 1	(1)	 1	(2)		 0	 0	
						Device	embolization	 1	(1)	 1	(2)	 0	 0	
						Valve	failure	 0	 0	 0	 	
	 	 	 	 	
 
Values are n (%). 
*Composite of all-cause mortality, all-cause stroke and TIA, bleeding (life-
threatening), acute kidney injury (Stage 2-3), major vascular complication, pericardial 
tamponade, device embolization, and valve failure.  
TIA = transient ischemic attack. 
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Table 3. Efficacy outcome of combined interventions vs. TAVR alone.  
	 Overall		(n	=103	)	
Concomitant	
(n	=52)	
Isolated	TAVR	
(n	=51)	
95%	conf.	
intervall	
	 	 	 	 	
*Composite	clinical	efficacy	EP		 81	(79)	 39	(75)	 42	(82)	 0.49	‐	2.92	
	 Late	all‐cause	mortality	 85	(83)	 42	(81)	 43	(84)	 0.37	‐	2.67	
	 Cardiovascular	 95	(92)	 47	(90)	 48	(94)	 0.28	‐	5.78	
	 Non‐cardiovascular	 93	(90)	 47	(90)	 46	(90)	 0.22	‐	3.08	
	 Late	all‐cause	stroke	and	TIA		 103	(100)	 52	(100)	 51	(100)	 	
	 Late	bleeding		 98	(95)	 48	(92)	 50	(98)	 0.41	‐	34.21	
†Composite	LAAO	efficacy	EP		 75	(73)	 36	(69)	 39	(76)	 0.54	‐	2.51	
	 All‐cause	mortality		 83	(81)	 41	(79)	 42	(82)	 0.39	‐	2.53	
											Cardiovascular	 95	(92)	 47	(90)	 48	(94)	 0.28	‐	5.78	
	 Non‐cardiovascular	 91	(88)	 46	(88)	 45	(88)	 0.26	‐	2.82	
	 Stroke	and	TIA	 99	(96)	 51	(98)	 48	(94)	 0.03	‐	3.06	
	 Ischemic	stroke	 99	(96)	 51	(98)	 48	(94)	 0.33‐3.06	
	 Hemorrhagic	stroke	 103	(100)	 52	(100)	 51	(100)	 	
	 Postprocedural	bleeding	 92	(89)	 45	(87)	 47	(92)	 0.53	‐	6.18	
 
Values are n (%). 
*Freedom from all-cause mortality, all-cause stroke (disabling and non-disabling) and 
TIA, and bleeding (life threatening and major). †Freedom from all-cause mortality, 
all-cause stroke (disabling and non-disabling) and TIA, and bleeding (life threatening 
and major).  
EP = endpoint; LAAO = left atrial appendage occlusion; TIA = transient ischemic 
attack. 
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Figures 
 
Figure 1. Fluoroscopic image of a combined procedure (left anterior oblique 20°, 
caudal 20°). 
Arrow A: Amulet 25 mm left atrial appendage occluder; Arrow B: Edwards Sapien 3 
26 mm transcatheter heart valve. 
 
Figure 2. Kaplan-Meier survival curve for each group: Freedom from composite 
safety outcome; 95% confidence interval 0.59	to	4.06. 
 
Figure 3. Kaplan-Meier survival curve for each group: Freedom from composite 
clinical efficacy outcome; 95% confidence interval 0.49	to	2.92.   
 
Figure 4. Kaplan-Meier survival curve for each group: Freedom from composite 
LAAO efficacy outcome; 95% confidence interval 0.54	to	2.51.   
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